- Avidity Biosciences specializes in targeted RNA therapeutics using its AOC platform.
- Their most advanced drug candidate, del-desiran, shows promising results in clinical trials for myotonic DM1.
- The company has achieved significant milestones, including FDA breakthrough therapy status and positive trial results, increasing the likelihood of FDA approval.
- Financially, Avidity Biosciences has a strong cash position of $915.9 million, providing a cash runway into 2027 and supporting its transition to a commercial-stage biotech.
- I rate RNA a “strong buy” due to its AOC platform, promising pipeline, and strong financials despite the inherent biotech risks.
Avidity Biosciences, Inc. (NASDAQ:RNA) specializes in targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates (AOC) platform. RNA can create therapies for previously unreachable tissues and cells with this approach. RNA’s platform provides monoclonal antibodies (mAbs) that accurately supply oligonucleotide treatments to interfere with or modify pathological gene expression and address the root causes of genetic diseases. RNA’s pipeline includes programs in phase 1/2 clinical trials. RNA’s most advanced drug candidate is del-desiran [AOC 1001], indicated for myotonic dystrophy type 1 (DM1). This last therapy seems to be on track to be approved by the FDA if its Phase 3 trials are successful. Hence, I think RNA is a compelling “strong buy” at these levels.
READ FULL ARTICLE HERE!
